drugset / Trial / NCT04246723
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1
Phase 2
Completed
85 enrolled
R-Pharm
Almedis · collabChromSystemsLab · collabScientific Center EFiS · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Multicenter, open-label, phase II safety and efficacy study of all-oral combination of narlaprevir/ritonavir and sofosbuvir in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1.
Timeline
- Start
- 2019-05-06
- Primary completion
- 2020-04-08
- Completion
- 2020-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Narlaprevir | Small molecule | 200 mg | Oral |
| Subject | Ritonavir | Other / unclassified | 100 mg | Oral |
| Subject | Sofosbuvir | Small molecule | 400 mg | Oral |